Hypophysitis is an inflammatory process affecting the pituitary gland that may variably involve the adenohypophysis, neurohypophysis, and pituitary stalk, resulting in a combination of symptoms caused by mass effect and endocrine dysfunction. Because the pituitary gland is the effector interface of hypothalamic integration, inflammation may lead to partial or complete hypopituitarism, sometimes accompanied by central diabetes insipidus when the posterior pituitary or stalk is involved. The clinical presentation is heterogeneous: it may develop subacutely with headache and fatigue, manifest through selective endocrine abnormalities, particularly corticotroph deficiency, or be identified during radiological follow-up of a sellar lesion.
From a nosological perspective, hypophysitis includes primary forms, which may be autoimmune or idiopathic, and secondary forms associated with systemic diseases, sellar lesions, or medications, with an increasing role played by hypophysitis related to cancer immunotherapy, particularly immune checkpoint inhibitors. Its clinical relevance lies in the risk of secondary adrenal insufficiency and in the need to distinguish a potentially reversible inflammatory process from adenomas and other sellar masses.
Hypophysitis, in its classic primary form, has traditionally been regarded as a rare cause of sellar disease and hypopituitarism. However, its apparent frequency has changed over time for two main reasons: the increased diagnostic sensitivity of hypothalamic-pituitary imaging and the emergence of iatrogenic forms associated with immune-modulating therapies. In historical case series, the most frequently described form is lymphocytic hypophysitis, which is often associated with autoimmune conditions and shows a predilection for women and for periods related to pregnancy and the postpartum phase, suggesting a role for immune recalibration during these stages.
A currently decisive epidemiological factor is hypophysitis induced by immune checkpoint inhibitors. In this setting, its frequency depends on the type of medication, the treatment combination, and the oncological context. The association is more typical with anti-CTLA-4 agents and may also occur with combination regimens, whereas with anti-PD-1 or anti-PD-L1 agents the radiological presentation may be less marked but still clinically significant, often dominated by corticotroph axis deficiency. In clinical practice, immunotherapy-induced hypophysitis has transformed a rare diagnosis into a condition that must be actively investigated in oncology, particularly when disproportionate systemic symptoms and electrolyte abnormalities develop.
The risk factors for primary hypophysitis include the presence of concomitant autoimmune diseases and, in some forms, a predisposition to organ-specific autoimmune conditions. In secondary forms, the risk factors reflect the underlying cause: sarcoidosis, histiocytosis, tuberculosis, and other systemic inflammatory disorders may involve the pituitary gland and stalk; IgG4-related diseases may cause pituitary involvement as part of a multiorgan fibroinflammatory disorder; metastases and infiltrative diseases may mimic or cause secondary hypophysitis. In these settings, the diagnostic probability increases when consistent extrasellar signs coexist and when central diabetes insipidus is prominent, because some infiltrative conditions preferentially involve the neurohypophysis and pituitary stalk.
Another risk profile is non-oncological iatrogenic hypophysitis, which is rarer but conceptually important. Some biological therapies and postoperative conditions may be associated with sellar inflammatory phenomena, and in patients with pre-existing pituitary lesions, superimposed inflammation may rapidly alter endocrine function. In general, the epidemiology of hypophysitis should be interpreted as a function of the clinical context: autoimmune and idiopathic forms predominate in conventional endocrinological practice, whereas in oncology the diagnosis must be incorporated into surveillance protocols for endocrine adverse events.
Finally, the clinical epidemiology is influenced by a practical issue: many cases are initially labelled as a “sellar mass” until clinical and radiological evolution, or histological assessment in the small proportion of patients who undergo surgery, clarifies the inflammatory nature of the lesion. This results in underestimation of mild or atypical forms and explains why risk-factor assessment should focus on identifying “sentinel contexts”: pregnancy or the postpartum period accompanied by headache and endocrine abnormalities, subacute onset of corticotroph deficiency with suggestive magnetic resonance imaging, central diabetes insipidus associated with pituitary stalk thickening, and cancer immunotherapy followed by the development of new systemic symptoms.
Hypophysitis may be interpreted as the result of immune and inflammatory activation directed against pituitary structures or as a secondary hypersensitivity response to a systemic trigger. The distinction between primary and secondary forms is not merely taxonomic, as it guides the extent of diagnostic investigations and the likelihood of involvement of other organs. In primary forms, the pituitary gland itself is the target, with infiltration by immune cells, oedema, possible necrosis, and subsequent fibrosis. In secondary forms, the pituitary gland is involved as part of a systemic disease, infection, infiltrative disorder, or medication-related response.
The histopathological variants describe different mechanisms through which inflammation alters pituitary architecture. The lymphocytic form is characterised by lymphoplasmacytic infiltration and may be associated with autoimmunity. The granulomatous form is characterised by granulomas and always requires a broad evaluation of potential causes, including infectious and systemic disorders. The xanthomatous form involves inflammation with accumulation of foamy macrophages. The IgG4-related form belongs to the spectrum of IgG4-related fibroinflammatory diseases and tends to behave as a more chronic process associated with fibrosis. The necrotising form is rare but conceptually important because of the rapidity with which it may cause loss of pituitary function. From a pathophysiological perspective, the common final effect is a reduction in pituitary reserve caused by oedema and cellular damage, with a variable compressive component involving the pituitary stalk.
In hypophysitis induced by immune checkpoint inhibitors, the pathogenesis occurs in the setting of immune system activation against tumour antigens, with loss of tolerance and development of organ-specific autoimmunity. Pituitary vulnerability in these patients produces a typical clinical pattern, with predominant corticotroph axis deficiency, sometimes accompanied by concomitant thyroid dysfunction of a different nature, such as autoimmune or destructive thyroiditis caused by immunotherapy. Inflammation may produce pituitary enlargement visible on magnetic resonance imaging in some cases, but endocrine severity is not necessarily proportional to the radiological findings, because even apparently limited involvement may selectively impair adrenocorticotropic hormone secretion and the ability to respond to stress.
When the process involves the neurohypophysis or pituitary stalk, the pathophysiology also affects vasopressin secretion. Loss of antidiuretic hormone secretion causes hypotonic polyuria and polydipsia, with a risk of hypernatraemia when access to water is limited or compensatory capacity is impaired. Pituitary stalk involvement also has another functional consequence: interruption of dopaminergic control may cause hyperprolactinaemia due to disinhibition. This finding does not indicate lactotroph hyperfunction but rather an alteration in central regulatory control and may provide a useful anatomical and functional clue when differentiating sellar masses.
At the level of individual hormonal axes, inflammation may cause multiple or selective deficiencies. Corticotroph deficiency reduces cortisol production and abolishes the stress response, increasing susceptibility to hypotension, hypoglycaemia, and shock during acute illness. Thyrotroph deficiency causes central hypothyroidism, with reduced basal metabolic rate, bradycardia, and neurocognitive slowing, accompanied by the characteristic absence of an appropriately increased thyroid-stimulating hormone concentration. Gonadotroph deficiency impairs steroidogenesis and reproductive function, affecting bone health and body composition. Growth hormone deficiency contributes to an adverse metabolic phenotype and impaired quality of life. Within this framework, hypophysitis should be understood as a loss of integrated regulation in which the dynamic component of pituitary secretion is particularly vulnerable. This may require stimulation testing in selected cases and establishes a therapeutic priority centred on the safety of the hypothalamic-pituitary-adrenal axis.
The clinical presentation of hypophysitis combines symptoms caused by mass effect and signs of endocrine dysfunction in variable proportions. Onset is often subacute, with progression over days or weeks, although more subtle presentations may occur. Conversely, rapidly progressive forms may develop when loss of adrenocorticotropic hormone precipitates clinically overt adrenal insufficiency. The medical history should reconstruct the chronology of symptoms, the presence of autoimmune disease, pregnancy or postpartum contexts, any oncological diagnosis and exposure to immunotherapy, as well as systemic signs that may suggest an infiltrative or infectious disorder.
Symptoms caused by mass effect include a new-onset headache or a headache that differs from a pre-existing pattern, sometimes accompanied by nausea, and visual disturbances when the optic chiasm is involved. Visual impairment is not invariably present, but when it occurs it suggests an active sellar process and requires prompt neuro-ophthalmological assessment. In some forms, headache may be severe and refractory and may represent the main reason for seeking medical attention, while endocrine symptoms emerge only after a targeted history is obtained.
From an endocrine perspective, the most critical abnormality is corticotroph deficiency, which may manifest as profound fatigue, orthostatic hypotension, nausea, anorexia, weight loss, exercise intolerance, and hypoglycaemia, with possible hyponatraemia. The absence of hyperpigmentation is consistent with secondary adrenal insufficiency. In oncology, the combination of marked fatigue, nausea, hypotension, and hyponatraemia during immunotherapy should always raise suspicion of hypophysitis and cortisol deficiency as a reversible cause of clinical deterioration.
Central hypothyroidism contributes to fatigue, drowsiness, cold intolerance, constipation, dry skin, and bradycardia, although these symptoms may be masked by concomitant adrenal insufficiency or other comorbidities. Gonadotroph deficiency causes amenorrhoea or oligomenorrhoea and reduced libido in women, and decreased sexual desire, erectile dysfunction, and reduced muscle mass in men. In acute forms, it may not be the presenting symptom, but it becomes clinically relevant over the medium term and during comprehensive assessment of multiaxial pituitary impairment.
Growth hormone deficiency in adults rarely determines the initial presentation, but it contributes to reduced vitality, deterioration in body composition and metabolic profile, and may amplify the perception of fatigue in patients with chronic hypophysitis. Prolactin deficiency is clinically relevant mainly in the postpartum period because it impairs lactation, whereas forms involving the pituitary stalk may cause hyperprolactinaemia due to dopaminergic disinhibition, providing a useful sign of disrupted regulatory control.
When the posterior pituitary is involved, the clinical picture may be dominated by polyuria and polydipsia with dilute urine, worsening during dehydration and carrying a risk of hypernatraemia when access to water is reduced. In these situations, the association with headache and signs of a sellar mass strengthens the suspicion of an inflammatory process involving the pituitary stalk and neurohypophysis and requires rapid management of electrolyte balance.
The physical examination may reveal hypotension, signs of dehydration, or features of hypothyroidism, reduced body hair, and signs of chronic hypogonadism. Neurological assessment and visual field examination are integral components of the evaluation, because hypophysitis is not only an endocrine diagnosis but also a potentially progressive sellar disorder that may require immediate diagnostic and therapeutic prioritisation.
Suspicion of hypophysitis arises when a sellar disorder and endocrine deterioration occur together with a temporal pattern compatible with inflammation, particularly when onset is subacute. In clinical practice, the most useful approach is to identify an at-risk patient who develops a recent or progressively worsening headache, marked fatigue, and signs of secondary adrenal insufficiency, with or without polyuria. Diagnosis is often delayed when symptoms are fragmented and attributed to stress, infection, or cancer progression, whereas hypophysitis requires a unifying interpretation.
A typical context is the onset of symptoms during pregnancy or the postpartum period, with headache and signs of multiaxial pituitary deficiency, particularly in the presence of a personal or family history of autoimmune disease. In this setting, differentiation from other obstetric causes of pituitary dysfunction is essential, because hypophysitis may present with a sellar mass and posterior pituitary involvement, whereas post-haemorrhagic ischaemic disorders have different clinical dynamics and signs. The development of central diabetes insipidus in a peripartum context suggests involvement of the neurohypophysis or pituitary stalk and requires dedicated assessment.
The second scenario, currently among the most clinically relevant, concerns oncology. During treatment with checkpoint inhibitors, the onset of severe fatigue, nausea, hypotension, headache, hyponatraemia, or hypoglycaemia should raise suspicion of hypophysitis and adrenocorticotropic hormone deficiency as a priority diagnosis. Interpretation of symptoms in these patients is particularly challenging because they may overlap with nonspecific adverse effects, infections, or disease progression, but recognition of adrenal insufficiency can substantially improve clinical stability.
A third context is the presence of central diabetes insipidus accompanied by imaging findings suggestive of pituitary stalk thickening, loss of the posterior pituitary signal on magnetic resonance imaging, and sellar abnormalities compatible with inflammation. This combination should prompt investigation for secondary causes, including infiltrative diseases, sarcoidosis, histiocytosis, and IgG4-related disorders, particularly when systemic symptoms or extrasellar organ involvement are also present.
Finally, suspicion is strong when an apparently adenomatous sellar mass is accompanied by rapidly worsening endocrine deficiency that is disproportionate to its size, or when serial imaging reveals inflammatory changes over time. In these cases, diagnosing hypophysitis may prevent unnecessary surgery and direct management towards a predominantly medical approach based on endocrine safety, selective treatment of inflammation, and structured follow-up.
The diagnosis of hypophysitis is based on the integration of the clinical presentation, hormonal profile, and hypothalamic-pituitary magnetic resonance imaging, through an assessment pathway that must prioritise the safety of the corticotroph axis. The first step is to establish whether secondary adrenal insufficiency is present, because it represents the greatest immediate risk. In practice, the initial assessment includes morning cortisol with adrenocorticotropic hormone, free thyroxine with thyroid-stimulating hormone, prolactin, gonadotropins with sex steroids, insulin-like growth factor 1 as a marker of the growth hormone-insulin-like growth factor axis, and, when compatible symptoms are present, assessment of water and electrolyte balance.
For the corticotroph axis, basal cortisol is conclusive only at extreme values, and many patients require dynamic testing in a specialist setting. In acute presentations with strong clinical suspicion, stabilisation and initiation of replacement therapy when indicated take priority, avoiding delays that increase the risk of adrenal crisis. Interpretation must consider the effects of concomitant therapies, the temporal course of the event, and the possibility that the deficiency may be selective and persistent, particularly in immunotherapy-induced hypophysitis.
For the thyrotroph axis, the diagnosis of central hypothyroidism requires a reduced free thyroxine concentration with a thyroid-stimulating hormone level that is not appropriately elevated. Reliance on thyroid-stimulating hormone alone must be avoided, because it may be normal or mildly elevated but biologically ineffective. At the same time, the diagnostic assessment must exclude confounding conditions such as non-thyroidal illness syndrome and consider the effects of glucocorticoids and dopaminergic agents, which may lower thyroid-stimulating hormone and alter its interpretation during the acute phase.
For the gonadotroph axis, diagnosis can often be established from basal concentrations interpreted according to age and reproductive context. In contrast, confirmation of growth hormone deficiency requires stimulation testing because growth hormone secretion is pulsatile and insulin-like growth factor 1 may be inconclusive in partial deficiencies or in the presence of comorbidities. Prolactin assessment has an anatomical and functional orienting role: elevated concentrations may reflect dopaminergic disinhibition caused by pituitary stalk involvement, whereas low concentrations may occur in more extensive destructive disease.
Assessment of water balance is essential when posterior pituitary involvement is suspected. The combination of polyuria, low urine osmolality, and abnormalities in serum sodium guides the evaluation of central diabetes insipidus and the differentiation of osmotic diuresis from other causes. In many cases, functional assessment must be performed cautiously to avoid electrolyte disturbances, particularly in frail or hospitalised patients.
Imaging with contrast-enhanced magnetic resonance imaging of the sellar region is central to supporting the diagnosis and differentiating hypophysitis from adenoma and other lesions. Suggestive findings include diffuse and relatively symmetrical pituitary enlargement, pituitary stalk thickening, abnormalities of the neurohypophysis, and enhancement patterns compatible with inflammation. However, no finding is absolute, and the diagnosis remains clinical and radiological. In oncology, for example, severe endocrine dysfunction may occur with minimal magnetic resonance abnormalities, whereas in other forms the sellar appearance may mimic a macroadenoma.
The diagnostic assessment should include investigation for secondary causes when suggested by the clinical context. The presence of central diabetes insipidus, pituitary stalk thickening, and systemic symptoms requires evaluation for infiltrative and inflammatory diseases. When IgG4-related disease is suspected, the assessment should extend beyond the sellar region and integrate clinical and laboratory findings. In selected cases involving visual impairment or diagnostic uncertainty, surgery may have a diagnostic and therapeutic role, but in most patients the diagnosis can be established through a well-structured clinical and radiological pathway.
The classification of hypophysitis integrates aetiology, histology, the anatomical compartment involved, and clinical impact. A first fundamental distinction separates primary from secondary forms. Primary forms include autoimmune or idiopathic disorders that directly affect the gland, whereas secondary forms result from systemic diseases, infections, infiltrative processes, neoplasms, or medications. This distinction guides the extent of investigations: in primary hypophysitis the focus is on endocrine management and assessment of autoimmunity, whereas in secondary hypophysitis the priority is to identify and treat the underlying disease.
A second level of classification is anatomical and distinguishes hypophysitis involving the adenohypophysis, neurohypophysis, pituitary stalk, or mixed forms involving the entire gland, known as panhypophysitis. This distinction is clinically useful because it predicts different endocrine patterns. Posterior pituitary and stalk involvement are more closely associated with central diabetes insipidus and hyperprolactinaemia caused by dopaminergic disconnection, whereas predominantly anterior hypophysitis may present with multiaxial hormone deficiencies without polyuria. In practice, functional anatomy helps interpret apparently nonlinear hormonal profiles and estimate the likelihood of specific aetiologies.
Histological classification describes variants with different clinical behaviours, including lymphocytic, granulomatous, xanthomatous, IgG4-related, and necrotising forms, as well as more recently described forms associated with pituitary autoimmunity. From a clinical perspective, histology is often presumed rather than demonstrated because biopsy is unnecessary in most cases. Nevertheless, knowledge of the histological spectrum is useful for understanding the variability in reversibility: processes dominated by oedema and inflammatory infiltration may improve, whereas those progressing towards fibrosis tend to cause permanent deficiencies.
A further classification category concerns iatrogenic hypophysitis related to cancer immunotherapy, which warrants a dedicated category because of its frequency, clinical context, and characteristic endocrine pattern. In these forms, severity should be assessed primarily according to corticotroph axis involvement and haemodynamic stability. Severity does not correspond to radiological size, and classification should include the chronicity of adrenocorticotropic hormone deficiency, which is often persistent and has prognostic and management implications.
Finally, the severity of hypophysitis should be defined in terms of immediate and long-term risk. Immediate risk is dominated by adrenal insufficiency and neuro-ophthalmological complications, whereas long-term risk reflects the metabolic, skeletal, and reproductive consequences of persistent hormonal deficiencies. This approach makes classification a dynamic process that must be updated during follow-up, because pituitary function may partially recover or, conversely, deteriorate as fibrosis progresses.
The treatment of hypophysitis has three integrated objectives: ensuring endocrine safety through appropriate hormone replacement, controlling the inflammatory process when indicated, and managing complications caused by mass effect, including visual disturbances. The order of treatment priorities is the same as in other causes of hypopituitarism: correction of adrenal glucocorticoid deficiency must precede thyroid hormone replacement, because the increase in metabolism induced by levothyroxine may precipitate an adrenal crisis in a patient with reduced cortisol reserve.
Glucocorticoid replacement is central when adrenocorticotropic hormone deficiency is present, both for controlling chronic symptoms and preventing adrenal crises. A key practical component is education regarding stress dosing, with clear instructions for temporary dose increases during fever, infection, vomiting, or surgical procedures, and access to emergency hydrocortisone when appropriate. In immunotherapy-induced forms, replacement may become permanent and should be managed carefully to avoid chronic over-replacement, which increases metabolic and skeletal risk.
Treatment of central hypothyroidism is based on levothyroxine, with dose titration guided by free thyroxine concentrations and the clinical picture because thyroid-stimulating hormone is unreliable in central disease. Gonadal hormone replacement follows the same principles used in hypogonadotropic hypogonadism: testosterone in men with appropriate safety monitoring, and oestrogen-progestogen therapy in women when indicated and individualised according to age and the risk-benefit profile. Dedicated treatment pathways are required when fertility is the objective, using exogenous gonadotropins and specialist monitoring.
Growth hormone therapy may be considered in adults with documented deficiency and compatible symptoms after stabilisation of the other hormonal axes, with monitoring of insulin-like growth factor 1 and clinical tolerance. In hypophysitis, the decision requires particular caution if the disease is active or if concomitant oncological conditions are present, and it should be integrated into radiological follow-up appropriate to the underlying cause.
When central diabetes insipidus is present, treatment with desmopressin must be adjusted to control polyuria without inducing dilutional hyponatraemia through excessive treatment. Education regarding water intake, warning signs, and electrolyte monitoring is as important as the prescription itself, because the principal risk is associated with preventable disturbances of water and electrolyte balance.
Control of inflammation using anti-inflammatory doses of glucocorticoids or other immunosuppressive strategies is selective and depends on the severity of the mass effect, visual impairment, aetiological diagnosis, and likelihood of reversibility. In cases involving optic chiasm compression or severe pain, reducing oedema may be beneficial. In patients with immunotherapy-induced hypophysitis, management must balance symptom control against oncological objectives and requires close coordination between endocrinology and oncology. Surgery is reserved for cases involving diagnostic uncertainty, refractory visual impairment, or the need for decompression. It may also provide a histological diagnosis, but it is not the first-line strategy in most patients.
Follow-up of hypophysitis is essential because endocrine function and sellar anatomy may evolve over time. Monitoring should assess three domains: clinical stability, the adequacy and safety of hormone replacement, and the radiological evolution of the pituitary or pituitary stalk lesion. The frequency of assessments depends on the activity and aetiology of the process. During the initial stages or in the presence of mass-effect symptoms, assessments should be frequent. In stabilised forms, follow-up becomes periodic but should remain long term because some deficiencies may persist and others may develop subsequently.
For the corticotroph axis, follow-up focuses on adherence, stress dosing, recognition of signs of under-replacement, and prevention of excessive treatment. In patients in whom recovery is considered possible, reassessment should be scheduled in a specialist setting because unsupervised discontinuation exposes the patient to the risk of adrenal crisis. In immunotherapy-induced hypophysitis, persistent adrenocorticotropic hormone deficiency is common and requires a chronic management approach with structured patient education.
During follow-up of central hypothyroidism, free thyroxine concentrations and the clinical picture guide levothyroxine dose adjustment. Changes in body weight, pregnancy, alterations in glucocorticoid therapy, and concomitant medications may modify treatment requirements and necessitate dose adjustment. For the gonadotroph axis, follow-up depends on the therapeutic objectives, including prevention of hypogonadism-related complications, safety monitoring of replacement therapy, and dedicated management when fertility is a priority.
Follow-up of the growth hormone axis, when treated, requires monitoring of insulin-like growth factor 1, body composition, metabolic parameters, and clinical tolerance, with attention to oedema, arthralgia, and blood glucose concentrations. In hypophysitis, symptoms should be interpreted globally because fatigue and mood disturbances may persist despite apparently adequate replacement, particularly when comorbidities coexist or inflammation has caused structural sequelae.
When central diabetes insipidus is present, follow-up includes plasma sodium, body weight, symptoms, and review of fluid intake habits, with clear instructions for temporary treatment adjustments during intercurrent illness. This is particularly important in patients in whom hypophysitis also affects other hormonal axes, because fluid management may become critical during vomiting, diarrhoea, or infection.
Radiological monitoring with magnetic resonance imaging is used to document resolution of oedema, stabilisation, or progression towards fibrosis and, importantly, to exclude alternative diagnoses when the clinical course is inconsistent with hypophysitis. In patients with cancer, follow-up should be coordinated with oncological treatment and surveillance of other endocrine adverse events, incorporating targeted assessments before and during therapy when indicated. Overall, structured follow-up is an integral component of treatment because it reduces the risk of preventable complications and allows hormone replacement to be adapted to a condition that may change over time.
The prognosis of hypophysitis depends on its aetiology, the severity of the initial presentation, the prompt recognition of corticotroph deficiency, and the management of mass effect. In many forms, the inflammatory component may decrease over time and symptoms caused by mass effect may improve, but endocrine function does not always recover completely. The most important clinical prognostic determinant is prevention of the complications of secondary adrenal insufficiency, which requires early diagnosis, adequate replacement therapy, and education regarding stress dosing.
The most dangerous complication is adrenal crisis in the presence of adrenocorticotropic hormone deficiency, precipitated by infection, surgery, trauma, or vomiting that prevents oral treatment. This risk is particularly relevant in immunotherapy-induced hypophysitis, in which corticotroph deficiency may persist and the initial symptoms may be confused with other conditions. Prevention is an integral component of prognosis and requires emergency plans, early recognition of symptoms, and appropriate dose adjustment during physiological stress.
Neuro-ophthalmological complications result from mass effect. Worsening visual fields, diplopia, and persistent headache require repeat neuroradiological assessment and, in some cases, decompression. In these situations, functional prognosis depends on the prompt recognition of visual impairment and the ability to reduce oedema or relieve compression when indicated. Even after inflammation has resolved, residual scarring may remain and require continued surveillance.
Over the long term, complications reflect the persistence of pituitary hormone deficiencies. Metabolic risk and cardiovascular risk are increased when growth hormone deficiency and hypogonadism coexist and may be further worsened by excessive glucocorticoid replacement. Osteopenia and fracture risk may result from prolonged hypogonadism and growth hormone deficiency. Reduced quality of life and neurocognitive symptoms may persist when replacement therapy is not optimised or when comorbidities coexist. Reproductive prognosis depends on the possibility of restoring or adequately replacing gonadotroph function and on access to specialist fertility care.
When the posterior pituitary is involved, the main complications are disturbances of water and electrolyte balance, including hypernatraemia caused by dehydration and hyponatraemia caused by excessive desmopressin treatment. Both are preventable through education and monitoring. Overall, the prognosis is favourable when hypophysitis is recognised early, the hypothalamic-pituitary-adrenal axis is protected, mass effect is managed appropriately, and hormone replacement is adjusted through structured follow-up. The dynamic nature of the disease makes it essential to regard hypophysitis as a condition that may evolve and requires long-term surveillance.